CA2662535A1 - Method for reducing or alleviating inflammation in the digestive tract - Google Patents

Method for reducing or alleviating inflammation in the digestive tract Download PDF

Info

Publication number
CA2662535A1
CA2662535A1 CA002662535A CA2662535A CA2662535A1 CA 2662535 A1 CA2662535 A1 CA 2662535A1 CA 002662535 A CA002662535 A CA 002662535A CA 2662535 A CA2662535 A CA 2662535A CA 2662535 A1 CA2662535 A1 CA 2662535A1
Authority
CA
Canada
Prior art keywords
carboxy
ethylamino
imidazol
ace2
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002662535A
Other languages
English (en)
French (fr)
Inventor
Louis Anthony Tartaglia
Thomas Michael Barnes
Robert Mark Coopersmith
Scott Edward Malstrom
David William White
Dominic Picarella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2662535A1 publication Critical patent/CA2662535A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002662535A 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract Abandoned CA2662535A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82507506P 2006-09-08 2006-09-08
US60/825,075 2006-09-08
US82780706P 2006-10-02 2006-10-02
US60/827,807 2006-10-02
PCT/US2007/077857 WO2008031014A1 (en) 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract

Publications (1)

Publication Number Publication Date
CA2662535A1 true CA2662535A1 (en) 2008-03-13

Family

ID=38670723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002662535A Abandoned CA2662535A1 (en) 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract

Country Status (11)

Country Link
US (1) US20080234345A1 (enExample)
EP (1) EP2059234B1 (enExample)
JP (1) JP2010502736A (enExample)
CN (1) CN101568331A (enExample)
AT (1) ATE531362T1 (enExample)
AU (1) AU2007292247A1 (enExample)
CA (1) CA2662535A1 (enExample)
DK (1) DK2059234T3 (enExample)
ES (1) ES2376493T3 (enExample)
IL (1) IL197362A0 (enExample)
WO (1) WO2008031014A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
WO2009114516A1 (en) * 2008-03-10 2009-09-17 Ore Pharmaceuticals Inc. Therapy for disorders of the proximal digestive tract
WO2010093804A1 (en) * 2009-02-12 2010-08-19 Ore Pharmaceuticals, Inc. Ace2 inhibitors for reducing gastrointestinal adverse effects of cytotoxic agents
EP2543388A4 (en) * 2010-03-04 2013-11-27 Dainippon Sumitomo Pharma Co MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
CN107530313A (zh) 2015-04-24 2018-01-02 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
GB202116266D0 (en) * 2021-11-11 2021-12-29 Bicycletx Ltd Novel use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US7045532B2 (en) * 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
WO2000066104A2 (en) * 1999-04-30 2000-11-09 Millennium Pharmaceuticals, Inc. Ace-2 inhibiting compounds and methods of use thereof
US6900033B2 (en) * 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity
GB0203061D0 (en) 2002-02-08 2002-03-27 Novartis Ag Organic compounds
HRP20050355A2 (en) * 2002-09-24 2005-10-31 Combinatorx Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
US20050203168A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of Michigan Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
US7842709B2 (en) * 2006-09-08 2010-11-30 Ore Pharmaceuticals Inc. Method for treating inflammatory diseases of the digestive tract

Also Published As

Publication number Publication date
AU2007292247A1 (en) 2008-03-13
EP2059234B1 (en) 2011-11-02
US20080234345A1 (en) 2008-09-25
DK2059234T3 (da) 2011-11-28
AU2007292247A2 (en) 2009-03-26
ATE531362T1 (de) 2011-11-15
IL197362A0 (en) 2009-12-24
EP2059234A1 (en) 2009-05-20
JP2010502736A (ja) 2010-01-28
ES2376493T3 (es) 2012-03-14
WO2008031014A1 (en) 2008-03-13
CN101568331A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
US7842709B2 (en) Method for treating inflammatory diseases of the digestive tract
EP2059234B1 (en) Method for reducing or alleviating inflammation in the digestive tract
US20120009183A1 (en) Method for treatment of pancreatitis
US20080300217A1 (en) Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders
CN106999593A (zh) 用于纤维化治疗的赛尼克韦罗组合疗法
US20060177444A1 (en) Concomitant drug as therapeutic agent for inflammatory bowel disease
JP2007531769A (ja) 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
US20250281397A1 (en) Formulations of a plasma kallikrein inhibitor
US20230381162A1 (en) Treatments of angioedema
WO2000000187A1 (fr) Compositions medicinales destinees au traitement de l'insuffisance d'evacuation
JP2003517443A (ja) 炎症性腸疾患を治療するための方法および組成物
JP2008515903A (ja) 拡張機能障害または拡張期心不全の予防または処置のためのレニン阻害剤の使用
US20100204286A1 (en) Method for reducing gastrointestinal adverse effects of cytotoxic agents
US20100035848A1 (en) Therapy for disorders of the proximal digestive tract
WO2022048618A1 (en) Methods to treat inflammatory bowel disease
US7858612B2 (en) Therapeutic agent for inflammatory bowel diseases
FR3090317A1 (fr) Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
TW202308623A (zh) 用於預防或治療纖維化之醫藥組成物
JP2022069377A (ja) 血管性浮腫の処置
HK40086505A (zh) 治疗炎性肠病的方法
JP2014520147A (ja) 疾患における組織トランスグルタミナーゼ活性化の調節
HK1250932A1 (en) Formulations containing diacerein and methods of lowering blood levels of uric acid using the same

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130909